Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -78.31%108K | 178.95%53K | 43.48%33K | -5.98%1.9M | 498K | 19K | 23K | 2.02M | 0 | 0 |
Operating revenue | -77.41%108K | 178.95%53K | 43.48%33K | -5.98%1.9M | --478K | --19K | --23K | --2.02M | --0 | --0 |
Cost of revenue | 2,625.93%1.47M | -7.48%1.22M | 54K | 1.32M | 0 | |||||
Gross profit | -78.31%108K | 213.22%2.13M | -4,541.94%-1.44M | -3.17%682.7K | 498K | 681K | -31K | 705.01K | 0 | |
Operating expense | 159.73%9.29M | 108.85%4.7M | 359.25%2.83M | -24.84%990.82K | 9.96%3.58M | 195.79%2.25M | 616K | 1.32M | -30.09%3.25M | 760K |
Selling and administrative expenses | 158.69%7.33M | 91.89%4.26M | 770.98%1.95M | -24.99%948.48K | 43.18%2.84M | 410.11%2.22M | --224K | --1.26M | 17.79%1.98M | --435K |
-Selling and marketing expense | 87.95%1.2M | 76.36%1.1M | 1,366.67%44K | 101.58%126 | 883.08%639K | 4,073.33%626K | --3K | ---7.97K | 225.00%65K | --15K |
-General and administrative expense | 179.28%6.13M | 97.99%3.15M | 762.90%1.91M | -25.47%948.36K | 14.67%2.2M | 279.29%1.59M | --221K | --1.27M | 15.29%1.92M | --420K |
Research and development costs | 163.70%1.95M | 1,406.90%437K | 123.98%878K | ---- | -41.75%741K | -91.08%29K | --392K | ---- | -56.53%1.27M | --325K |
Depreciation amortization depletion | ---- | ---- | ---- | -21.12%42.34K | ---- | ---- | ---- | --53.67K | --0 | ---- |
-Depreciation and amortization | ---- | ---- | ---- | -21.12%42.34K | ---- | ---- | ---- | --53.67K | --0 | ---- |
Operating profit | -198.25%-9.18M | -63.50%-2.56M | -559.66%-4.27M | 49.75%-308.12K | 5.35%-3.08M | -106.18%-1.57M | -647K | -613.21K | 29.61%-3.25M | -760K |
Net non-operating interest income expense | -283.33%-69K | -560.00%-33K | -700.00%-24K | 71.84%-10.37K | 96.86%-18K | 89.58%-5K | -3K | -36.81K | -325.19%-574K | -48K |
Non-operating interest expense | 283.33%69K | 560.00%33K | 700.00%24K | -71.84%10.37K | -96.86%18K | -89.58%5K | --3K | --36.81K | 325.19%574K | --48K |
Other net income (expense) | -344.74%-1.21M | -339.52%-1.19M | 3K | -106.44%-71.21K | 1,235.14%494K | 8,166.67%496K | 1.11M | -90.11%37K | 6K | |
Gain on sale of security | -491.89%-145K | ---146K | ---2K | ---- | --37K | ---- | ---- | ---- | ---- | ---- |
Special income (charges) | ---874K | ---- | ---- | -106.68%-73.95K | --0 | ---- | ---- | --1.11M | 117.24%30K | --2K |
-Less:Restructuring and merger&acquisition | ---- | ---- | ---- | -78.00%73.95K | ---- | ---- | ---- | --336.14K | ---- | ---- |
-Less:Impairment of capital assets | --874K | ---- | ---- | ---- | --0 | ---- | ---- | ---- | --79K | --0 |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---1.44M | -86.86%59K | --0 |
-Write off | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -105.88%-2K | ---- |
-Gain on sale of property,plant,equipment | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -46.28%166K | --0 |
Other non- operating income (expenses) | -141.58%-190K | -136.60%-168K | --5K | 1,991.60%2.74K | 6,428.57%457K | 11,375.00%459K | ---- | --131 | 333.33%7K | --4K |
Income before tax | -301.92%-10.46M | -251.58%-3.78M | -559.85%-4.29M | -185.38%-389.7K | 31.33%-2.6M | -34.16%-1.08M | -650K | 456.44K | 13.51%-3.79M | -802K |
Income tax | 100.00%2K | 100.00%2K | 0 | 0 | 1K | 1K | 0 | 0 | 0 | 0 |
Earnings from equity interest net of tax | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---221.65K | ---- | ---- |
Net income | -301.84%-10.46M | -251.44%-3.79M | -559.85%-4.29M | -265.98%-389.7K | 31.30%-2.6M | -34.29%-1.08M | -650K | 234.79K | 13.51%-3.79M | -802K |
Net income continuous Operations | -301.84%-10.46M | -251.44%-3.79M | -559.85%-4.29M | -265.98%-389.7K | 31.30%-2.6M | -34.29%-1.08M | ---650K | --234.79K | 13.51%-3.79M | ---802K |
Minority interest income | ||||||||||
Net income attributable to the parent company | -301.84%-10.46M | -251.44%-3.79M | -559.85%-4.29M | -265.98%-389.7K | 31.30%-2.6M | -34.29%-1.08M | -650K | 234.79K | 13.51%-3.79M | -802K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -301.84%-10.46M | -251.44%-3.79M | -559.85%-4.29M | -265.98%-389.7K | 31.30%-2.6M | -34.29%-1.08M | -650K | 234.79K | 13.51%-3.79M | -802K |
Basic earnings per share | -383.77%-1.6 | -228.84%-0.45 | -638.60%-0.61 | -265.98%-0.0495 | 31.30%-0.3307 | -34.29%-0.1368 | -0.0826 | 0.0298 | 13.51%-0.4814 | -0.1019 |
Diluted earnings per share | -383.77%-1.6 | -228.84%-0.45 | -638.60%-0.61 | -265.98%-0.0495 | 31.30%-0.3307 | -34.29%-0.1368 | -0.0826 | 0.0298 | 13.51%-0.4814 | -0.1019 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |